234 related articles for article (PubMed ID: 22913713)
21. Improvement of tardive dyskinesia and dystonia associated with aripiprazole following a switch to quetiapine: case report and review of the literature.
Ono S; Suzuki Y; Shindo M; Endo T; Fukui N; Sugai T; Someya T
J Clin Pharm Ther; 2012 Jun; 37(3):370-2. PubMed ID: 22023382
[TBL] [Abstract][Full Text] [Related]
22. Aripiprazole, Ziprasidone and Quetiapine in the treatment of first-episode nonaffective psychosis: a 12-week randomized, flexible-dose, open-label trial.
Crespo-Facorro B; Ortiz-García de la Foz V; Mata I; Ayesa-Arriola R; Suarez-Pinilla P; Valdizan EM; Vázquez-Barquero JL; Pérez-Iglesias R
Schizophr Res; 2013 Jul; 147(2-3):375-82. PubMed ID: 23643328
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness of aripiprazole, olanzapine, quetiapine, and risperidone augmentation treatment for major depressive disorder: a nationwide population-based study.
Lin CY; Tsai GE; Wang HS; Wu YH; Chiou CC; Wu VY; Lane HY
J Clin Psychiatry; 2014 Sep; 75(9):e924-31. PubMed ID: 25295435
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial.
Zink M; Kuwilsky A; Krumm B; Dressing H
J Psychopharmacol; 2009 May; 23(3):305-14. PubMed ID: 18562423
[TBL] [Abstract][Full Text] [Related]
25. Comparative effectiveness of switching antipsychotic drug treatment to aripiprazole or ziprasidone for improving metabolic profile and atherogenic dyslipidemia: a 12-month, prospective, open-label study.
Chen Y; Bobo WV; Watts K; Jayathilake K; Tang T; Meltzer HY
J Psychopharmacol; 2012 Sep; 26(9):1201-10. PubMed ID: 22234928
[TBL] [Abstract][Full Text] [Related]
26. An analysis of safety and tolerability data from controlled, comparative studies of quetiapine in patients with schizophrenia, focusing on extrapyramidal symptoms.
Timdahl K; Carlsson A; Stening G
Hum Psychopharmacol; 2007 Jul; 22(5):315-25. PubMed ID: 17542047
[TBL] [Abstract][Full Text] [Related]
27. Second-generation antipsychotics in major depressive disorder: update and clinical perspective.
Chen J; Gao K; Kemp DE
Curr Opin Psychiatry; 2011 Jan; 24(1):10-7. PubMed ID: 21088586
[TBL] [Abstract][Full Text] [Related]
28. The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials.
Glick ID; Mankoski R; Eudicone JM; Marcus RN; Tran QV; Assunção-Talbott S
J Affect Disord; 2009 May; 115(1-2):18-26. PubMed ID: 19230981
[TBL] [Abstract][Full Text] [Related]
29. Aripiprazole as a viable alternative for treating delusions of parasitosis.
Ladizinski B; Busse KL; Bhutani T; Koo JY
J Drugs Dermatol; 2010 Dec; 9(12):1531-2. PubMed ID: 21120263
[TBL] [Abstract][Full Text] [Related]
30. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
31. Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders.
McDougle CJ; Stigler KA; Erickson CA; Posey DJ
J Clin Psychiatry; 2008; 69 Suppl 4():15-20. PubMed ID: 18533764
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of atypical antipsychotic drugs (quetiapine, risperidone, aripiprazole and paliperidone) compared with placebo or typical antipsychotic drugs for treating refractory schizophrenia: overview of systematic reviews.
Melnik T; Soares BG; Puga ME; Atallah AN
Sao Paulo Med J; 2010 May; 128(3):141-66. PubMed ID: 20963366
[TBL] [Abstract][Full Text] [Related]
33. Sex differences in the effect of four second-generation antipsychotics on QTc interval in patients with schizophrenia.
Suzuki Y; Sugai T; Fukui N; Watanabe J; Ono S; Tsuneyama N; Saito M; Someya T
Hum Psychopharmacol; 2013 May; 28(3):215-9. PubMed ID: 23553637
[TBL] [Abstract][Full Text] [Related]
34. Epidemiologic study of aripiprazole use and the incidence of suicide events.
Ulcickas Yood M; Delorenze G; Quesenberry CP; Tsai AL; Phillips S; Willey VJ; Niemcryk SJ; Wells K; Skovron ML; Cziraky MJ; Carson W; Oliveria SA
Pharmacoepidemiol Drug Saf; 2010 Nov; 19(11):1124-30. PubMed ID: 20925132
[TBL] [Abstract][Full Text] [Related]
35. Early intervention with second-generation antipsychotics in first-episode psychosis: results of an 8-week naturalistic study.
Josiassen RC; Shaughnessy RA; Filymer DM; Donohue AM; Kacso M; Finkel N; Curtis J; Audino B; Skuban N
Early Interv Psychiatry; 2010 Feb; 4(1):57-63. PubMed ID: 20199481
[TBL] [Abstract][Full Text] [Related]
36. Aripiprazole: review of its pharmacology and therapeutic use in psychiatric disorders.
Gupta S; Masand P
Ann Clin Psychiatry; 2004; 16(3):155-66. PubMed ID: 15517848
[TBL] [Abstract][Full Text] [Related]
37. Extrapyramidal side effects associated with aripiprazole administration in a schizophrenic patient.
Hung GC; Chen YY
Pharmacopsychiatry; 2007 Mar; 40(2):83-4. PubMed ID: 17447180
[No Abstract] [Full Text] [Related]
38. Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons.
Rummel-Kluge C; Komossa K; Schwarz S; Hunger H; Schmid F; Kissling W; Davis JM; Leucht S
Schizophr Bull; 2012 Jan; 38(1):167-77. PubMed ID: 20513652
[TBL] [Abstract][Full Text] [Related]
39. Tardive dyskinesia in affective disorders.
Kane JM
J Clin Psychiatry; 1999; 60 Suppl 5():43-7; discussion 48-9. PubMed ID: 10192407
[TBL] [Abstract][Full Text] [Related]
40. Comparing tolerability of olanzapine in schizophrenia and affective disorders: a meta-analysis.
Moteshafi H; Zhornitsky S; Brunelle S; Stip E
Drug Saf; 2012 Oct; 35(10):819-36. PubMed ID: 22967188
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
